Menu
Search
|

Menu

Close
X

Myriad Genetics Inc MYGN.OQ (NASDAQ Stock Exchange Global Select Market)

26.30 USD
+0.31 (+1.19%)
As of Jul 17
Previous Close 25.99
Open 26.09
Volume 143,342
3m Avg Volume 330,547
Today’s High 26.45
Today’s Low 25.79
52 Week High 50.43
52 Week Low 22.09
Shares Outstanding (mil) 73.37
Market Capitalization (mil) 1,906.98
Forward P/E 143.60
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.82 Mean rating from 11 analysts

KEY STATS

Revenue (mm, USD)
FY19
636
FY18
745
FY17
770
FY16
754
EPS (USD)
FY19
0.117
FY18
1.739
FY17
0.309
FY16
1.875
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
143.60
34.16
Price to Sales (TTM)
vs sector
2.30
8.16
Price to Book (MRQ)
vs sector
1.76
4.38
Price to Cash Flow (TTM)
vs sector
22.95
24.12
Total Debt to Equity (MRQ)
vs sector
24.35
18.17
LT Debt to Equity (MRQ)
vs sector
24.35
13.01
Return on Investment (TTM)
vs sector
1.04
12.64
Return on Equity (TTM)
vs sector
1.33
17.19

EXECUTIVE LEADERSHIP

John Henderson
Independent Chairman of the Board, Since 2005
Salary: --
Bonus: --
Mark Capone
President, Chief Executive Officer, Director, Since 2015
Salary: $852,000.00
Bonus: --
W. Lloyd Sanders
President, Myriad Oncology, Since 2018
Salary: --
Bonus: --
Mark Verratti
President - Myriad Neuroscience, Since 2018
Salary: --
Bonus: --
Walter Gilbert
Independent Vice Chairman of the Board, Since
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Advanced Medical Equipment & Technology
Address:

320 S Wakara Way
SALT LAKE CITY   UT   84108-1214

Phone: +1801.5843600

Myriad Genetics, Inc. is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk for developing disease later in life, identify a patient's likelihood of responding to drug therapy and guide a patient's dosing to enable optimal treatment, or assess a patient's risk of disease progression and disease recurrence. The other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services, such as finance, human resources, legal and information technology. Its molecular diagnostic tests include myRisk Hereditary Cancer, BRACAnalysis CDx and COLARIS.

SPONSORED STORIES